A new hereditary persistence of fetal hemoglobin deletion has the breakpoint within the 3' beta-globin gene enhancer
- PMID: 1689188
A new hereditary persistence of fetal hemoglobin deletion has the breakpoint within the 3' beta-globin gene enhancer
Abstract
A new deletion of the beta-globin gene cluster has been characterized in two Italian brothers who are heterozygous carriers of a G gamma A gamma hereditary persistence of fetal hemoglobin (HPFH). Restriction endonuclease mapping and DNA sequencing of the region encompassing the breakpoint show that the deletion starts 3.2 kilobases (kb) upstream from the delta gene and ends within the enhancer region 3' to the beta-globin gene. Here the deletion removes one of the four binding sites for an erythroid specific transcriptional factor (NF-E1). The molecular comparison of the new deletion with others of similar size and location but associated with a delta beta-thalassemia phenotype suggests that the residual enhancer element, relocated near gamma genes, may increase the fetal hemoglobin (HbF) expression above the level observed in delta beta-thalassemia.
Similar articles
-
The breakpoint of a large deletion causing hereditary persistence of fetal hemoglobin occurs within an erythroid DNA domain remote from the beta-globin gene cluster.Blood. 1989 Nov 1;74(6):2178-86. Blood. 1989. PMID: 2478223
-
Molecular comparison of delta beta-thalassemia and hereditary persistence of fetal hemoglobin DNAs: evidence of a regulatory area?Proc Natl Acad Sci U S A. 1982 Apr;79(7):2347-51. doi: 10.1073/pnas.79.7.2347. Proc Natl Acad Sci U S A. 1982. PMID: 6179097 Free PMC article.
-
Sequences located 3' to the breakpoint of the hereditary persistence of fetal hemoglobin-3 deletion exhibit enhancer activity and can modify the developmental expression of the human fetal A gamma-globin gene in transgenic mice.J Biol Chem. 1995 Apr 28;270(17):10256-63. doi: 10.1074/jbc.270.17.10256. J Biol Chem. 1995. PMID: 7537267
-
Delta beta thalassemia and hereditary persistence of fetal hemoglobin.Hematol Oncol Clin North Am. 1991 Jun;5(3):399-422. Hematol Oncol Clin North Am. 1991. PMID: 1713909 Review.
-
Molecular basis of hereditary persistence of fetal hemoglobin.Ann N Y Acad Sci. 1998 Jun 30;850:38-44. doi: 10.1111/j.1749-6632.1998.tb10460.x. Ann N Y Acad Sci. 1998. PMID: 9668525 Review.
Cited by
-
Molecular mechanism of high hemoglobin F production in Southeast Asian-type hereditary persistence of fetal hemoglobin.Int J Hematol. 2006 Apr;83(3):229-37. doi: 10.1532/IJH97.E0509. Int J Hematol. 2006. PMID: 16720553
-
Concise Review: Epigenetic Regulation of Hematopoiesis: Biological Insights and Therapeutic Applications.Stem Cells Transl Med. 2017 Dec;6(12):2106-2114. doi: 10.1002/sctm.17-0192. Epub 2017 Oct 28. Stem Cells Transl Med. 2017. PMID: 29080249 Free PMC article. Review.
-
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.Haematologica. 2006 Aug;91(8):1076-83. Haematologica. 2006. PMID: 16885048 Free PMC article.
-
Deletion of a region that is a candidate for the difference between the deletion forms of hereditary persistence of fetal hemoglobin and deltabeta-thalassemia affects beta- but not gamma-globin gene expression.EMBO J. 1999 Feb 15;18(4):949-58. doi: 10.1093/emboj/18.4.949. EMBO J. 1999. PMID: 10022837 Free PMC article.
-
Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10661-5. doi: 10.1073/pnas.1612075113. Epub 2016 Sep 6. Proc Natl Acad Sci U S A. 2016. PMID: 27601644 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources